{"id":540450,"date":"2021-09-21T08:33:26","date_gmt":"2021-09-21T12:33:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/"},"modified":"2021-09-21T08:33:26","modified_gmt":"2021-09-21T12:33:26","slug":"brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/","title":{"rendered":"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Sept.  21, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IUcRZ6nIjwMmOtf8Ylug_vECFMBvWVY7ADcXci0l97lDoWUC-ZxgNV6tR8TkQ0a05l97hq5P5FdHrudEAiptCge43es4RpfTupomz3PhmuHdlu2AIPELMjUDiJAGrbAq\" rel=\"nofollow noopener\" target=\"_blank\">Brooklyn ImmunoTherapeutics, Inc<\/a>. (NYSE American: BTX) (\u201cBrooklyn\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience\u2019s Co-founder and Chief Executive Officer.<\/p>\n<p>The call was based on Brooklyn\u2019s most recent corporate slide deck, which can be found <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aOsU4y73OzCb_8Iqccj9mWPG0aaccqyxv-ohJ-KQS0MUt-qxr7M4UljVSfUYikvD8aU58kH2Q6q9ebcW9CfvfJoL2BPnoZufSZFcggnTBbU=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p>Highlights of the call included:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Brooklyn is building on its license from Factor Bioscience, its acquisition of Novellus Therapeutics and its placement of its R&amp;D facility at 1035 Cambridge Street alongside Factor Bioscience<\/li>\n<li style=\"margin-bottom:8pt\">Brooklyn plans to use iMSCs \u2014 mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs) \u2014 to address allogeneic bone marrow transplants that have functioned poorly or have failed to address the cancer associated with the procedure<\/li>\n<li style=\"margin-bottom:8pt\">Brooklyn plans to apply its gene editing products to solid tumors<\/li>\n<li style=\"margin-bottom:8pt\">Brooklyn outlined its proposed approach for gene editing products to treat monogenic disorders by targeting the liver, brain and eye<\/li>\n<li style=\"margin-bottom:8pt\">Dr. Federoff described Brooklyn\u2019s expected approach to autologous iPSCs with gene editing to address problems such as sickle cell disease<\/li>\n<li style=\"margin-bottom:8pt\">Based on intellectual property licensed from Factor Bioscience, Brooklyn\u2019s highly efficient mRNA strategy is designed to preclude cellular innate immune responses and, when coupled with a tunable nanolipid delivery system such as the ToRNAdo system, could allow Brooklyn to address clinical problems that have not been addressable before<\/li>\n<\/ul>\n<p align=\"justify\">Replays of the call are available by calling US Toll Free<strong> 1-877-344-7529\u00a0<\/strong>or International Toll 1-412-317-0088 and using replay access code 10160132 through October 3, 2021. The webcast can also be replayed until December 20, 2021 at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NI9WPesl9xeiOmCPI2S7acI6q7F-KYaCt8obLFh8g7b1Q1TltGSo4OmIQY983eCdXJfI2xNQrmPc66znBqTVqLMEr5UkfZSr4UaLi_eNZHiwfyJTvqxHWQTW67u_XBvC3p0KWxnrwNlfdNGXeJ3-XJhs60XbM62EM3TMMZiV6XeacZRGX9TD_G-xMW86mx7trxtUDRDy24mAFiHUtSt_wZ3Nz-g4VuJtTzjmzDg8DTs=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/services.choruscall.com\/mediaframe\/webcast.html?webcastid=FBeOvP50<\/a> or on Brooklyn\u2019s website in the Investor Relations section under \u201cEvents.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Brooklyn ImmunoTherapeutics<\/strong><br \/>\n        <br \/>Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.<\/p>\n<p align=\"justify\">Brooklyn\u2019s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.<\/p>\n<p align=\"justify\">Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iDgSq1xhhpCXOiPDjO0t9B6pkqWEmxZkLK5u2SCnCONVoErkOvbcmdGxiYx5T12i5RYcGf5HGsAcSLjVvyw6WKF3ISfGD-semnLMbESfs9Y=\" rel=\"nofollow noopener\" target=\"_blank\">www.BrooklynITx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Trademark<\/strong><br \/>\n        <br \/>\n        <em>ToRNAdo is a trademark of Factor Bioscience Limited.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>The second through sixth bulleted items in the third paragraph of this release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of historical fact and may be identified by terminology such as \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201cwill\u201d or other similar words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to, uncertainties related to: (i) the evolution of Brooklyn\u2019s business model into a platform company focused on cellular, gene editing and cytokine programs; (ii)\u00a0Brooklyn\u2019s ability to successfully, cost-effectively and efficiently develop its technology and products; (iii)\u00a0Brooklyn\u2019s ability to successfully commence clinical trials of any products on a timely basis or at all; (iv)\u00a0Brooklyn\u2019s ability to successfully fund and manage the growth of its development activities; (v)\u00a0Brooklyn\u2019s ability to obtain regulatory approvals of its products for commercialization; and (vi) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Brooklyn, including on the timing and cost of its clinical trials. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this release speak only as of September 20, 2021, the date of the Shareholder Update Conference Call, and Brooklyn does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after such date, except as may be required by applicable law or regulation. \u00a0Factors that may impact Brooklyn&#8217;s success are more fully disclosed in Brooklyn&#8217;s public filings with the Securities and Exchange Commission, particularly under \u201cRisk Factors\u201d or similar headings.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/>516-222-2560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S_59WoQrS_cNXwFBiX1CcaWkN8kJwMT9K4yLcKoWdMHf2-OVGV4OCLcjSA_aGjKLcp2rrHWmsqDB2OXQxEVBzOQ-9vHwAf7iLl5zVR8Qt-E=\" rel=\"nofollow noopener\" target=\"_blank\">investors@brooklynitx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>CORE IR<br \/>917-885-7378<br \/>julesa@coreir.com<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGFjMmExNGQtYTMxNi00ZDMyLTk0Y2EtZWE2YmM5NDBhYjNjLTEyMjE4MzM=\/tiny\/Brooklyn-Immunotherapeutics-LL.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) &#8212; Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (\u201cBrooklyn\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience\u2019s Co-founder and Chief Executive Officer. The call was based on Brooklyn\u2019s most recent corporate slide deck, which can be found here. Highlights of the call included: Brooklyn is building on its license from Factor Bioscience, its acquisition of Novellus Therapeutics and its placement of its R&amp;D facility &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-540450","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) &#8212; Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (\u201cBrooklyn\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience\u2019s Co-founder and Chief Executive Officer. The call was based on Brooklyn\u2019s most recent corporate slide deck, which can be found here. Highlights of the call included: Brooklyn is building on its license from Factor Bioscience, its acquisition of Novellus Therapeutics and its placement of its R&amp;D facility &hellip; Continue reading &quot;Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-21T12:33:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021\",\"datePublished\":\"2021-09-21T12:33:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/\"},\"wordCount\":848,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/\",\"name\":\"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=\",\"datePublished\":\"2021-09-21T12:33:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/","og_locale":"en_US","og_type":"article","og_title":"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 - Market Newsdesk","og_description":"NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) &#8212; Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (\u201cBrooklyn\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience\u2019s Co-founder and Chief Executive Officer. The call was based on Brooklyn\u2019s most recent corporate slide deck, which can be found here. Highlights of the call included: Brooklyn is building on its license from Factor Bioscience, its acquisition of Novellus Therapeutics and its placement of its R&amp;D facility &hellip; Continue reading \"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-21T12:33:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021","datePublished":"2021-09-21T12:33:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/"},"wordCount":848,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/","name":"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=","datePublished":"2021-09-21T12:33:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyOTQwMSM0NDE1MzU1IzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-september-20-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/540450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=540450"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/540450\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=540450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=540450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=540450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}